Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Receivables (2024 - 2025)

Gossamer Bio's Receivables history spans 2 years, with the latest figure at $12.5 million for Q4 2025.

  • For Q4 2025, Receivables rose 126.2% year-over-year to $12.5 million; the TTM value through Dec 2025 reached $12.5 million, up 126.2%, while the annual FY2025 figure was $12.5 million, 126.2% up from the prior year.
  • Receivables reached $12.5 million in Q4 2025 per GOSS's latest filing, up from $9.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $12.5 million in Q4 2025 to a low of $3.9 million in Q2 2024.